Navigation Links
avVaa World Health Care Products Inc. Announces Second DRTV Test Week
Date:10/1/2009

LUMBY, BC, Oct. 1 /PRNewswire-FirstCall/ - avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced that they will be launching their second test run of Neuroskin(R) Psoriasis Relief DRTV commercials the week of October 5, 2009.

avVaa World Health Care Products will launch a two week DRTV test run for Neuroskin(R) Psoriasis Relief beginning the week of October 5, 2009. The first week will feature a 2 minute soft offer commercial, and the second week will feature a 2 minute hard offer commercial. While the hard offer displays the product price of $34.95, the soft offer displays no price. Each offer has benefits and drawbacks, and the test will help determine which one produces the best sales.

"With the hard offer, the price is given up front, and many customers like that," stated Lorie Campbell-Farley, President and Chief Operating Officer. "But those customers may only purchase one unit, because their cost expectation was set when watching the commercial. A soft offer will generate more inquiries, and customers may be more easily upsold, however some callers will end the conversation when they find out the price. The goal is to find which offer works best with Neuroskin(R)."

The DRTV commercials are in infomercial format. Over 50 commercials will run each week, most being 2 minutes long. "Synergixx is working with the networks to get us additional free spots for 60 and 30 second commercials," commented Mrs. Campbell-Farley. To facilitate this, Creative Bube Tube has added a 30 second DRTV commercial to Neuroskin's(R) DRTV repertoire.

"With our first media test, we were able to work out the kinks in our processes and in vendor communications. We took what we learned and made the changes that were needed, such as changing media buyers, adding echeck, and streamlining our credit card processing. We're ready to hit the road running with this test, and we anticipate a much better return on our investment," concluded Lorie Campbell-Farley.

About avVaa World Health Care Products

avVaa World Health Care Products is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin(R)) line of skin care products through mass, food and drug channels in the United States and globally. The Company's secondary line of equine and pet care related products are already being distributed throughout all of Canada. For more information, visit: www.avvaa.com.

Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of avVaa World Health Care Products, Inc. and no assurance can be given that such results will be achieved.

Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.

CONTACT: Jack Farley, Chairman/CEO, jfarley@avvaa.com; Lorie Campbell-Farley, President/COO, lcfarley@avvaa.com; Investor Relations: Merle Goertz (West Coast), (604) 688-2349

SOURCE avVaa World Health Care Products


'/>"/>
SOURCE avVaa World Health Care Products
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. avVaa World Health Care Products, Inc. Announces the completion of its first week of DRTV 120/60 second test commercials for Neuroskin(R) Psoriasis Relief
2. avVaa World Health Care Products Inc. Announces Web Site Design for Neuroskin(R) Psoriasis Relief DRTV Campaign
3. avVaa World Health Care Products, Inc. Signs Agreement with 3PL Worldwide, Inc., for Order Management & Fulfillment for avVaas Product
4. avVaa World Health Care Products, Inc. Announces Engagement of Koeppel Direct for their DRTV-Direct Response Television Media Buying Campaign
5. Healthnostics Unveils Biomedical Content Strategy for Medbioworld.com
6. Reportlinker Adds World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The Report
7. Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM)
8. Will Jatropha Become a 'DotCom Bubble' in Biofuel Industry? Leading to 2nd JatrophaWorld Africa, Jatropha Webinar on 30 Sept 09 Explores Challenges & Offers Strategies for Long-Term Success for This Non-Food Crop for Fuel
9. Leading Cardiovascular Surgeons Gather from Around the World to Share Ross Procedure Survival Data, Techniques at 2nd Annual Summit
10. AstraZeneca and Nektar Sign Worldwide Agreement for Nektar Drug Development Programmes -- NKTR-118 and NKTR-119 -- to Address Opioid-Induced Constipation
11. Childrens Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... MD (PRWEB) , ... January 18, 2017 , ... ... the National Institutes of Health (NIH) to update its Data Sharing Policy. Specifically, ... “scoreable” element of grant applications subject to the existing policy. AMIA recommended that ...
(Date:1/19/2017)... 18, 2017  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW ... therapies for operable and inoperable solid tumor cancers, announced ... Officer of NW Bio, will present at the Phacilitate ... the Hyatt Regency Hotel in Miami, Florida ... session entitled "New Therapeutic Approaches – Expanding the Reach ...
(Date:1/18/2017)... 2017   Boston Biomedical , an industry leader ... cancer stemness pathways, will feature data from two clinical ... 2017 ASCO Gastrointestinal Cancers Symposium, held from January 19-21, ... Napabucasin is an orally-administered investigational agent designed to ... Cancer stem cells (CSCs) possess the property of stemness ...
(Date:1/18/2017)... , ... January 18, 2017 , ... ... and more E&L expertise. Within Albany Molecular Research, Inc. (AMRI), the scientific staff ... past year and is planned for further growth in 2017. Extractable & Leachable ...
Breaking Biology Technology:
(Date:12/19/2016)... , España y TORONTO , 19 de diciembre ... Northern Biologics Inc. que permitirá el desarrollo acelerado de MSC-1, un ... en varios tipos de tumor en 2017, con múltiples sitios previstos ... ... clase con objetivo en el factor inhibidor de leucemia (LIF), una ...
(Date:12/15/2016)... and BADEN-BADEN, Germany , December ... leading global financial services provider, today announced an agreement with ... behavioural biometrics, to join forces. The partnership will enable clients ... strategies in compliance with local data protection regulation. ... In order to ...
(Date:12/15/2016)... , Dec. 15, 2016  There is much more ... or starting the engine. Continental will demonstrate the intelligence ... Las Vegas . Through the combination of the ... Entry) and biometric elements, the international technology company is ... personalization and authentication. "The integration of biometric ...
Breaking Biology News(10 mins):